Nordson Corporation Q2 FY26 Earnings Analysis

- Nordson expects continued above-market organic growth driven by accelerating demand in key end markets such as semiconductor, electronics, and medical. - Full year sales guidance increased to a range of $2.930 billion to $3.010 billion, with high confidence in the midpoint. - Strong backlog up 18%, broad-based across all segments, signaling sustained order momentum. - The Advanced Technology Solutions (ATS) segment shows notable strength with double-digit backlog growth and ongoing strength in semiconductor demand. - Medical segment targeting normalized growth rates of 6-8%, supported by order entry and backlog build-up. - Industrial Precision segment growing at 4% organically, with improving trends in plastics and coatings. - Continued growth expected from precision agriculture after recent acquisition of CapstanAG. - Confidence maintained despite macroeconomic uncertainties, with prudent outlook for potential raw material or customer pullback risks.

- Nordson expects to continue returning to normalized growth rates in medical segment, targeting 6% to 8% growth. - Industrial Precision Solutions shows improving demand and 4% organic growth, with best-in-class margins targeted. - Advanced Technology Solutions (ATS) segment backlog up 18% with strong momentum, indicating durable demand. - Incremental EBITDA improved in the quarter and expected to return to normal incremental performance as the year progresses. - Adjusted earnings per share for Q2 rose 18% YoY to a record $2.86, exceeding guidance by $0.06. - Full-year adjusted effective tax rate is expected within 18%-19%, slightly better than prior guidance, supporting sustainable profitability. - Strong free cash flow ($170 million) and improved leverage ratio (1.9x net debt to EBITDA) provide capacity for disciplined strategic investments and shareholder returns. - No fundamental change in backlog timing, with most backlog converting within 6 months, supporting near-term earnings visibility. - The company remains cautiously optimistic, watching macro uncertainties but confident in underlying demand drivers.

- $10 million invested in capital projects during the quarter to support current and future organic growth (Page 3). - Strategic acquisition of CapstanAG, a precision agriculture technology leader in North America, to grow precision agriculture portfolio and expand product offerings (Pages 2 and 4). - Ongoing M&A activity with a robust pipeline, focused on disciplined acquisitions meeting strategic and financial criteria, especially in medical, test and inspection, and bolt-on technology for existing businesses (Page 9). - $900 million capacity remaining for acquisitions, indicating future potential strategic investments (Page 9). - Capital allocation balances growth investment, shareholder returns, and debt reduction, supporting sustainable franchise growth (Page 3).

- There is no indication of any new fundraising through debt or equity in the transcript. - The company reported strong cash flow generation ($170 million free cash flow in Q2) and significant financial capacity (about $900 million in capacity remaining). - Net debt was approximately $1.8 billion with a leverage ratio of 1.9x, which is below the company's long-term target range. - The company has been actively managing debt, including reducing net debt by $93 million in the quarter. - Focus remains on disciplined M&A activity funded through existing cash flow and capacity. - No explicit plans or statements about upcoming equity raises or additional debt issuance were mentioned.

- Backlog is up 18%, with all segments contributing to strong order momentum (Page 9). - ATS segment shows robust backlog growth, likely in double digits, contributing significantly to overall backlog increase (Page 9). - Majority of backlog converts within 6 months; some portion extends into 2027 but remains a minority (Page 8). - Lead times have improved from 16-18 weeks to less than 7-8 weeks, with some systems shipping within the quarter (Page 10). - Order entry and backlog buildup in Medical segment support confidence in returning to normalized growth (Page 5). - Strong order momentum across all segments, providing high confidence at the midpoint of sales guidance (Page 10). - No fundamental change in delivery requests; order lead times remain typical without longer-term order hoarding (Page 11).